# Multi-ancestry meta-analyses of lung cancer in the Million Veteran Program reveal novel risk loci and elucidate smoking-independent genetic risk

Bryan R. Gorman<sup>1,2</sup>, Sun-Gou Ji<sup>1,15</sup>, Michael Francis<sup>1,2</sup>, Anoop K. Sendamarai<sup>1,16</sup>, Yunling Shi<sup>1</sup>, Poornima Devineni<sup>1</sup>, Uma Saxena<sup>1</sup>, Elizabeth Partan<sup>1</sup>, Andrea K. DeVito<sup>1,2</sup>, Jinyoung Byun<sup>11,12</sup>, Younghun Han<sup>11,12</sup>, Xiangjun Xiao<sup>11,12</sup>, Don D. Sin<sup>3</sup>, Wim Timens<sup>4,5</sup>, Jennifer Moser<sup>6</sup>, Sumitra Muralidhar<sup>6</sup>, Rachel Ramoni<sup>6</sup>, Rayjean J. Hung<sup>7</sup>, James D. McKay<sup>8</sup>, Yohan Bossé<sup>9</sup>, Ryan Sun<sup>10</sup>, Christopher I. Amos<sup>11,12,13</sup>, VA Million Veteran Program, Saiju Pyarajan<sup>1,14,‡</sup>

<sup>1</sup>Center for Data and Computational Sciences (C-DACS), VA Boston Healthcare 12 System, Boston, MA, USA, <sup>2</sup>Booz Allen Hamilton, McLean, VA, USA, <sup>3</sup>The University of 13 British Columbia Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, 14 British Columbia, Canada, <sup>4</sup>University Medical Centre Groningen, GRIAC (Groningen) 15 Research Institute for Asthma and COPD), University of Groningen, Groningen, 16 Netherlands, <sup>5</sup>Department of Pathology & Medical Biology, University Medical Centre 17 18 Groningen, University of Groningen, Groningen, Netherlands, <sup>6</sup>Office of Research and Development, Department of Veterans Affairs, Washington, DC, USA. <sup>7</sup>Lunenfeld-19 Tanenbaum Research Institute, Sinai Health System, University of Toronto, Toronto, 20 Ontario, Canada, <sup>8</sup>Section of Genetics, International Agency for Research on Cancer, 21 World Health Organization, Lyon, France, <sup>9</sup>Institut universitaire de cardiologie et de 22 pneumologie de Québec, Department of Molecular Medicine, Laval University, Quebec 23 City, Quebec, Canada, <sup>10</sup>Department of Biostatistics, University of Texas MD Anderson 24 Cancer Center, Houston, TX, USA, <sup>11</sup>Institute for Clinical and Translational Research, 25 Baylor College of Medicine, Houston, TX, USA, <sup>12</sup>Department of Medicine, Section of 26 27 Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX, USA, <sup>13</sup>Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, 28 TX, USA, <sup>14</sup>Department of Medicine, Brigham and Women's Hospital, Harvard Medical 29 School, Boston, MA, USA, <sup>15</sup>Present address: Sun-Gou Ji, BridgeBio Pharma, Palo 30 Alto, CA, USA, <sup>16</sup>Present address: Carbone Cancer Center, University of Wisconsin, 31 Madison, WI, USA. <sup>‡</sup>Saiju Pyarajan: saiju.pyarajan@va.gov 32

33

1

2

3 4

5

6

7 8

9

# 34 Abstract

35 Lung cancer remains the leading cause of cancer mortality, despite declines in smoking 36 rates. Previous lung cancer genome-wide association studies (GWAS) have identified 37 numerous loci, but separating the genetic risks of lung cancer and smoking behavioral 38 susceptibility remains challenging. We performed multi-ancestry GWAS meta-analyses 39 of lung cancer using the Million Veteran Program (MVP) cohort and a previous study of 40 European-ancestry individuals, comprising 42,102 cases and 181,270 controls, followed by replication in an independent cohort of 19,404 cases and 17,378 controls. We further 41 42 performed conditional meta-analyses on cigarettes per day and identified two novel. replicated loci, including the 19p13.11 pleiotropic cancer locus in LUSC. Overall, we 43 44 report twelve novel risk loci for overall lung cancer, lung adenocarcinoma (LUAD), and 45 squamous cell lung carcinoma (LUSC), nine of which were externally replicated. Finally, we performed phenome-wide association studies (PheWAS) on polygenic risk scores 46 (PRS) for lung cancer, with and without conditioning on smoking. The unconditioned 47 48 lung cancer PRS was associated with smoking status in controls, illustrating reduced predictive utility in non-smokers. Additionally, our PRS demonstrates smoking-49 50 independent pleiotropy of lung cancer risk across neoplasms and metabolic traits.

## 52 Introduction

Lung cancer remains the leading cause of overall cancer mortality, as the most 53 prevalent cancer type in men, and the second highest in women after breast cancer<sup>1-3</sup>. 54 Despite declines in smoking rates in the US since the 1980s<sup>4</sup>, tobacco use is currently 55 implicated in upwards of 80% of lung cancer diagnoses<sup>1</sup>. Even in those who have never 56 smoked, nor had meaningful exposure to environmental carcinogens<sup>1,5</sup>, there exists a 57 heritable risk component of lung cancer conferred by genetic factors<sup>6–8</sup>. Differentiating 58 the mutations which directly predispose an individual to lung cancer from those whose 59 effect is mediated through environmental components remains challenging. 60

61 Genome-wide association studies (GWAS) have identified lung cancer risk variants associated with oncogenic processes such as immune response<sup>7</sup>, cell cycle 62 regulation<sup>9</sup>, and those affecting DNA damage response and genomic stability<sup>8</sup>. Several 63 lung cancer GWAS have also reported strong effects of genes such as CHRNA nicotine 64 65 receptor genes which putatively increase the risk of lung cancer through behavioral predisposition towards smoking<sup>5</sup>. Characteristic molecular markers and genetic risk 66 factors in smokers and never-smokers have been identified<sup>10,11</sup>, though fewer variants 67 have been found in GWAS performed exclusively in never-smokers<sup>12</sup>. 68

Lung cancer has a heterogeneous genetic architecture across ancestral groups<sup>13,14</sup>. In the two most well-studied ancestries, European (EA) and East Asian (EAS), the majority of genome-wide significant loci are not shared<sup>15,16</sup>; this is in agreement with molecular studies showing differences in tumor characteristics between EA and EAS<sup>17</sup>. Smaller African ancestry (AA) cohorts have replicated known loci from EA or EAS<sup>8,18</sup>, though no AA-specific GWAS loci have been reported.

75 In this study, we examined lung cancer genetic variation in EA as well as in the 76 largest AA cohort to-date. Our discovery analysis is performed in an older cohort of mostly male US veterans in the Department of Veterans Affairs Million Veteran Program 77 (MVP)<sup>19</sup>. Lung cancer incidence is approximately twice as high in men than in women<sup>2</sup>. 78 79 and additionally MVP contains a large number of cigarette smokers, positioning this 80 biobank as particularly valuable for this analysis. We performed GWAS in overall cases 81 of lung cancer as well as two non-small cell lung cancer (NSCLC) subtypes, adenocarcinoma (LUAD) and squamous cell lung carcinoma (LUSC). 82

83

### 84 **Results**

### 85 Genome-wide association studies for lung cancer

We performed a GWAS on overall lung cancer within EA participants in MVP 86 87 (10,398 lung cancer cases and 62,708 controls; Supplementary Data 1), followed by a 88 meta-analysis with the EA International Lung Cancer Consortium OncoArray study (ILCCO; McKay et al., 2017)<sup>7</sup>, for a total of 39,781 cases and 119,158 controls 89 90 (Supplementary Fig. 1). The EA meta-analysis for overall lung cancer identified 26 conditionally independent SNPs within 17 genome-wide significant loci ( $P < 5 \times 10^{-8}$ ; 91 Supplementary Fig. 2a; Supplementary Data 2). All 12 loci reported by ILCCO<sup>7</sup> were 92 93 confirmed, with consistent direction of effect on all single nucleotide polymorphisms (SNPs) with  $P < 1 \times 10^{-5}$ , as well as high correlation of effect sizes and allele frequency 94 95 (Supplementary Fig. 3). Of the 17 genome-wide significant loci for overall lung cancer, four were novel with respect to the broader literature: neuronal growth regulator 96

*LSAMP*, WNT signaling regulator *NMUR2*, DNA damage repair protein *XCL2*, and
hedgehog signaling regulator *TULP3*, (Table 1; Supplementary Fig. 4a-d).

Further association tests stratified by cancer subtypes LUAD and LUSC in MVP 99 100 EA (Supplementary Fig. 2bc; Supplementary Data 3-4) replicated associations reported by ILCCO<sup>7</sup> (Supplementary Fig. 3) and identified additional loci. Two novel EA meta-101 102 analysis loci were identified for LUAD, proto-oncogene MYC and Wnt signaling inhibitor 103 TLE3 (Table 1; Supplementary Fig. 4e-h). For LUSC, we identified one novel locus at 104 10q24.31 near NFkB inhibitor CHUK and BLOC1S2. Across all subtypes for EA meta-105 analysis index variants, the MVP cohort had associations with P<0.05 in all but one in 106 overall lung cancer, five in LUAD, including approximately nominal significance at 107 rs67824503 (MYC; P=0.057), and one in LUSC (Supplementary Data 2-4).

We investigated expression quantitative trait loci (eQTL) relationships between top SNPs from the EA meta-analysis across all lung cancer GWAS in GTEx v8 Lung<sup>20</sup> and the Lung eQTL Consortium<sup>21</sup> (Supplementary Data 2-4). This analysis showed that the LUSC index SNP rs36229791 on 10q24.31 was associated with the mRNA expression levels of *BLOC1S2* (Fig. 1a-d), consistent with previous TWAS<sup>22</sup>. *BLOC1S2* is an oncogene whose gene product is associated with centrosome function; centrosomal abnormalities have previously been observed *in vitro* in LUSC<sup>23,24</sup>.

We improved our variant selection by fine-mapping and estimating credible sets of candidate causal variants in EA meta analysis using sum of single effects (SuSiE)<sup>25,26</sup> modeling. For overall lung cancer, LUAD, and LUSC, we identified 23, 23, and 9 high quality credible sets, respectively, containing 370, 246, and 192 total SNPs (Supplementary Data 5).

120

#### 121 GWAS in AA

We analyzed overall lung cancer risk in 2,438 cases and 62,112 controls of African ancestry (AA), the largest AA GWAS discovery cohort to date (Supplementary Fig. 5a). Two loci reached genome-wide significance in our discovery scan: 15q25, replicating the association in *CHRNA5* for AA populations reported by an earlier GWAS<sup>18</sup>, and a putative novel locus at 12q23 with index SNP rs78994068 (Table 1; Fig. 1e). We further performed GWAS in AA within LUAD and LUSC subtypes but found no genome-wide significant associations (Supplementary Fig. 5b-c).

129 The putative AA locus at 12q23 is driven by six SNPs in high linkage 130 disequilibrium (LD;  $R^2$ >0.8) found in long non-coding RNAs LINC00943 and LINC00944 131 (Fig. 1e). These imputed SNPs all had odds ratios (ORs) close to 2, with 1.3% 132 frequency in AA and 0% in EA, consistent with gnomAD v3. LINC00944 is highly 133 expressed in immune cells and blood, and enriched in T cell pathways in lung tissue and cancer<sup>27-30</sup>. We fine-mapped this locus to define a 95% credible set 134 (Supplementary Data 6), and annotated the functional consequence of the variants 135 using the Variant Effect Predictor (VEP)<sup>31</sup>. Two variants, rs78994068 and rs115962601, 136 137 were in a known enhancer regulatory region (ENSR00000974920) and thus may involve regulatory changes. However, this locus was directionally consistent but not significant 138 139 in our AA replication cohort (discussed below); therefore, larger-scale AA analyses are 140 needed to confirm this finding.

### 142 GWAS multi-ancestry meta-analysis

We conducted a fixed-effect inverse variance-weighted multi-ancestry meta-143 analysis, combining the EA meta-analysis and the MVP AA GWAS for overall lung 144 145 cancer, LUAD, and LUSC (Supplementary Data 7-9; Supplementary Fig. 6a-c). This 146 analysis identified two additional novel genome-wide significant loci in overall lung 147 cancer (Table 1; Supplementary Fig. 4i-j): ubiquitin ligase JADE2, previously associated with smoking initiation<sup>32</sup>, and RNA polymerase-associated *RPAP3*. Neither of these 148 149 novel multi-ancestry meta-analysis loci were reported in a recent multi-ancestry analysis by Byun et al.<sup>8</sup> that included fewer AA and more Asian ancestry samples, indicating the 150 151 value our larger AA sample provided for novel discovery. All genome-wide significant 152 EA meta-analysis associations reached genome-wide significance in the multi-ancestry meta-analysis except rs11855650 (*TLE3*) in LUAD ( $P=6.19\times10^{-8}$ ). We additionally 153 performed random effects meta-analyses using the Han-Eskin method (RE2)<sup>33</sup>, and 154 155 observed similar P-values to the fixed effect meta-analysis, with all index variants  $P_{\text{RE2}}$ <5×10<sup>-8</sup> (Supplementary Data 7-9). 156

157

### 158 Polygenic risk scoring

To gain an understanding of the penetrance and pleiotropy of lung cancer risk, we constructed PRSs based on the ILCCO summary statistics<sup>7</sup> for every EA subject in MVP. As expected, the PRS was highly associated with both lung cancer risk as well as smoking behavior (Supplementary Fig. 7a-b). Even after removing individuals with any history of lung cancer risk to prevent enrichment of risk factors and comorbidities, the association with smoking behavior remained, suggesting that the PRS is partially

165 capturing genetic smoking behavioral risk factors (Supplementary Fig. 7c). In all groups,
166 individuals at the top decile of the PRS were at significantly higher risk of lung cancer
167 than those in the lowest decile.

168 Multi-trait conditional analysis for smoking status

Despite adjusting for smoking status, both in MVP EA and ILCCO<sup>7</sup>, a significant 169 170 genetic correlation was observed between all subsets of lung cancer GWAS and a recently published GWAS of smoking behaviors<sup>34</sup> (Fig. 2a, Supplementary Data 10). In 171 172 order to remove all residual effects of smoking on lung cancer susceptibility, we conducted a multi-trait-based conditional and joint analysis (mtCOJO)<sup>35,36</sup>, conditioning 173 on a GWAS for cigarettes per day<sup>34</sup>, which was the smoking trait most strongly 174 175 correlated with overall lung cancer and subtype GWAS from the EA meta-analysis. 176 Because lung cancer case selection also preferentially selects smokers, conventional 177 adjustment for smoking may inadvertently cause selection bias, which functions as a collider to induce biased genetic effects<sup>37</sup>. mtCOJO is considered more robust to 178 potential collider bias than conventional covariate adjustment<sup>35,36</sup>. The total observed-179 scale SNP-heritability<sup>38</sup> of lung cancer risk decreased substantially after conditioning on 180 181 cigarettes per day, from 5.4% to 3.1% in overall LC, from 6.7% to 5.5% in LUAD, and 182 from 5.8% to 3.8% in LUSC (Fig. 2b; Supplementary Data 11).

Significant loci from the conditional analyses are shown in Supplementary Fig. 8-9 and Supplementary Data 12-14. As expected, the statistical significance of loci harboring smoking-related genes (e.g., *CHRNA5*, *CYP2A6*, *CHRNA4*) dropped to below genome-wide significance after conditioning (Fig. 3). Conversely, five signals (four loci) became significant only after conditioning, including novel signals at *MMS22L* in overall

188 lung cancer and 19p13.1 (ABHD8) in LUSC. MMS22L is a novel GWAS signal but was 189 previously identified as overexpressed in lung cancer in genome-wide gene expression scan<sup>39</sup>. These may represent biological lung cancer signals partially masked by 190 191 countervailing genetic effects on smoking behavior. We performed fine-mapping to 192 identify candidate causal variants in the conditioned EA meta-analysis summary 193 statistics, and for overall lung cancer, LUAD, and LUSC, we identified 11, 15, and 6 high 194 quality credible sets, respectively, containing a total of 243, 277, and 78 SNPs 195 (Supplementary Data 5).

We constructed PRS based on mtCOJO-conditioned ILCCO summary statistics<sup>7</sup> to directly compare the predictive performance of PRS derived from the conditioned and non-conditioned GWAS in MVP EA. While the PRS based on the non-conditioned overall lung cancer GWAS exhibited reduced performance in never-smokers compared to ever-smokers, the PRS based on the conditional analysis resulted in similar performance across smoking status (Fig. 2c; Supplementary Data 15).

202

203 Replication of novel variants in OncoArray and combined meta-analysis

We queried the OncoArray Consortium Lung Study (OncoArray) as an external non-overlapping replication dataset for our significant GWAS signals (Supplementary Data 16-17). For GWAS in EA meta-analysis for overall lung cancer, LUAD, and LUSC, we replicated five of seven novel loci (*P*<0.01) in an OncoArray European ancestry cohort: *XCL2* and *TLE3* in overall lung cancer, *MYC* and *TLE3* in LUAD, and *BLOC1S2* in LUSC. The novel African ancestry association for overall lung cancer at *LINC00944* was not replicated. We meta-analyzed OncoArray European and African ancestry

211 participants to replicate our multi-ancestry meta-analysis signals for overall lung cancer 212 at RPAP3 (P=0.0044) and JADE2 which bordered on nominal significance (rs329122; 213 P=0.053). For the two novel loci which were identified in EA meta-analysis conditioned 214 on cigarettes per day, we included smoking as a covariate for association analysis in 215 the OncoArray European ancestry cohort. These association signals were replicated for 216 overall lung cancer at MMS22L (P=0.006) and LUSC at ABHD8 (P=0.003). In a variant-217 level replication of 137 conditionally independent discovery associations which fell 218 within ≤1 Mb of a previously reported lung cancer GWAS signal, 134 had P<0.05 in OncoArray, and 42 had  $P < 5 \times 10^{-8}$  (Supplementary Data 18). 219

220 We then performed a combined meta-analysis of our discovery results with 221 OncoArray replication results (Supplementary Data 18). We considered a conservative threshold of  $P=4.17 \times 10^{-9}$  ( $P=5 \times 10^{-8}/12$  total GWAS analyses) to be significant, which 222 223 was met by 9 of the 12 loci. Because rs329122 in JADE2 achieved the more conservative significance threshold ( $P=3.69\times10^{-9}$ ), and has also been associated with 224 smoking behavior<sup>32</sup> and identified as a splicing-related variant associated with lung 225 cancer<sup>40</sup>, we considered this locus to be replicated. In the combined meta-analysis we 226 227 observed similar P-values in fixed effects and random effects (RE2) models.

Next, for all previously reported lung cancer and subtype loci in this study, we identified lung cancer associations from GWAS Catalog which fell within the same loci as our index variants (Supplementary Data 19). We confirmed two loci that previously had been reported only in a recent genome-wide association by proxy (GWAx) of lung cancer<sup>41</sup>: *CENPC* (rs75675343) in overall lung cancer in the EA meta-analysis (*P*=2.40×10<sup>-8</sup>) and the multi ancestry meta-analysis, and *TP53BP1* in overall lung

cancer in the multi-ancestry meta-analysis (rs9920763;  $P=1.63 \times 10^{-8}$ ). Our multiancestry meta-analysis for overall lung cancer also confirmed a recently reported locus at 4q32.2 (*NAF1*)<sup>15</sup> in East Asian ancestry.

237

238 Multi-trait analysis with breast cancer

At 19p13.1, a known pleiotropic cancer locus<sup>42,43</sup>, the index SNP of LUSC 239 240 conditioned on smoking (rs61494113) sits in a gene-rich region where a recent finemapping effort of breast cancer risk loci<sup>44</sup> proposed two independent associations, one 241 affecting the regulation of ABHD8 and MRPL34, and another causing a coding mutation 242 243 in ANKLE1. Here, we used the increased power provided by a multi-trait analysis of GWAS (MTAG)<sup>45</sup> of LUSC and estrogen receptor negative (ER-) breast cancer<sup>46</sup> to 244 245 disentangle the complex relationships between cancer risk and the genes in this locus 246 (Fig. 4a). Overexpression of ABHD8 has been shown to significantly reduce cell migration<sup>42,43</sup>. Similar odds ratios at rs61494113 were observed across LUSC and 247 248 breast cancer, and MTAG enhanced the GWAS signal at this locus (Fig. 4b).

We used the coloc-SuSiE method<sup>47</sup> to assess colocalized associations between pairs of credible sets in this locus underlying the risk of LUSC and ER– breast cancer, allowing for multiple causal signals. We found evidence for a shared causal signal between credible sets in the LUSC conditional meta-analysis and ER– breast cancer (97.7% posterior probability; Supplementary Data 20). The index SNPs for the credible sets of LUSC conditioned on smoking and ER– breast cancer (rs61494113 and rs56069439, respectively) have  $r^2$ =0.99.

256 The eQTL effect of ABHD8 was replicated in multiple tissues of GTEx v8, including Lung (Fig. 4c). Interestingly, the group of SNPs in the LUSC-BC credible set 257 258 did not have the most significant eQTL effect, suggesting a complex relationship 259 between the multiple causal variants at the locus and gene expression (Fig. 4d). For instance, a recent splice variant analysis<sup>48</sup> implicated splicing of BABAM1 (a BRCA1-260 261 interacting protein) as a culprit of the associations observed in 19p13.1. Consistent with previous reports<sup>42,43</sup>, the cancer risk-increasing haplotype was correlated with increased 262 263 expression of ABHD8 and alternative splicing of BABAM1. However, there was no overlap between the 95% eQTL credible sets of ABHD8 and BABAM1, and neither of 264 the credible sets included rs61494113. 265

266

#### 267 *Phenome-wide association study*

268 Finally, to investigate the pleiotropy of lung cancer genetic risk in the absence of 269 the overwhelming effect of smoking behavior, we performed PheWAS in MVP using the PRS scores constructed from the ILCCO summary statistics<sup>7</sup> for overall lung cancer, 270 271 both based on the standard GWAS ("unconditioned PRS"; Fig. 5a; Supplementary Data 272 21) and the GWAS conditioned on cigarettes per day using mtCOJO ("conditioned 273 PRS"; Fig. 5b; Supplementary Data 22). Each PRS was tested for association with 274 1,772 phecode-based phenotypes. Overall, 240 phenotypes were associated with the 275 unconditioned PRS and 112 were associated with the conditioned PRS at a Bonferroni-276 corrected significance threshold (P<0.05/1,772). Although lung cancer remained a top 277 association with the conditioned PRS, the association with tobacco use disorder was 278 greatly reduced, from an OR associated with a standard deviation increase in the PRS

of 1.151 [1.142-1.160] (P=2.32×10<sup>-237</sup>) in the unconditioned PRS to OR=1.046 [1.038-279 1.053] ( $P=1.05\times10^{-32}$ ) in the conditioned PRS. However, the effect on alcohol use 280 281 disorder was only modestly attenuated between the unconditioned (OR=1.098 [1.089-1.108];  $P=1.05\times10^{-87}$ ) and conditioned LC (OR=1.078 [1.069-1.088],  $P=4.41\times10^{-60}$ ) 282 PRSs. Whether a role for alcohol in lung cancer exists independently of smoking is 283 controversial<sup>49,50</sup>; this analysis suggests that may be the case. Other putatively 284 285 smoking-related associations, such as chronic obstructive pulmonary disease, 286 pneumonia, and peripheral vascular disease were greatly diminished with the 287 conditioned PRS. Mood disorders, depression, and post-traumatic stress disorder, were 288 also significantly associated with the unconditioned PRS but no longer significantly 289 associated with the conditioned PRS, reflecting neuropsychiatric correlates of smoking 290 behavior.

Intriguingly, a category of metabolic traits that were not associated with the 291 292 unconditioned PRS were highly associated with the conditioned PRS and in a negative 293 effect direction. We observed protective associations of the conditioned PRS with metabolic traits such as type 2 diabetes (OR=0.945 [0.938-0.952], P=9.46×10<sup>-52</sup>) and 294 obesity (OR=0.952 [0.945-0.959],  $P=2.48\times10^{-41}$ ). Neither were associated with the 295 296 unconditioned PRS (OR=1.006 [0.999-1.014]; P=0.092, and OR=1.005 [0.998-1.012]; 297 P=0.183, respectively). Other traits in this category included sleep apnea and 298 hyperlipidemia. These findings are consistent with prior observational findings of an inverse relationship between BMI and lung cancer<sup>51</sup> and illustrate the extent to which 299 300 smoking may be a major confounder of this relationship.

301 Finally, we observed strong associations of the lung cancer PRS with skin cancer 302 and related traits, such as actinic keratitis. In basal cell carcinoma, the OR increased from 1.087 [1.072-1.102] (P=6.06×10<sup>-32</sup>) with the unconditioned PRS to 1.105 [1.090-303 1.120] ( $P=1.82\times10^{-47}$ ) with the conditioned PRS. As a sensitivity analysis, we tested the 304 305 strength of this association after removing the TERT locus, which is prominently 306 associated with both traits. Doing so only modestly reduced the effect of the conditioned PRS to OR=1.092 [1.077-1.107] (P=4.08×10<sup>-36</sup>). Thus, our results are consistent with a 307 308 genome-wide genetic correlation between lung cancer and basal cell carcinoma that is 309 strengthened when the effect of smoking is removed. Overall, our results suggest that 310 the biology underlying lung cancer risk may be partially masked by the residual genetic 311 load of smoking.

312

### 313 **Discussion**

314 We identified novel lung cancer-associated loci in a new cohort of EA and AA 315 participants, including the largest AA cohort analyzed to-date. We also show that, 316 despite studies on the genetic basis of lung cancer risk taking smoking status into 317 account, the effects of smoking continue to obfuscate our understanding of lung cancer 318 genetics. In particular, we report two novel loci, at MMS22L (overall) and ABHD8 319 (LUSC), which may be partially masked by countervailing genetic effects on smoking. 320 Our replication analysis which adjusted for smoking pack-years confirmed these loci. 321 Additionally, our analyses demonstrated that PRSs for lung cancer contain large 322 uncorrected genetic loading for smoking behavioral factors. Our results indicate that 323 controlling for these factors can improve risk assessment models, potentially improving

lung cancer screening even for non-smokers. Finally, our phenomic scans comparing
 PRSs derived from GWAS with and without genomic conditioning on smoking showed
 divergent associations across numerous traits, especially metabolic phenotypes.

327 The increased sample size in this study enabled the interpretation of multiple 328 causal variants underlying the gene-rich ADHL8-BABAM1 region, synthesizing prior 329 observations into a clearer understanding of this locus. Our other novel loci strengthen 330 established lung cancer mechanisms. We identify for the first time a susceptibility locus 331 at MYC, a well-known oncogene and master immune regulator. XCL2 is involved in cellular response to inflammatory cytokines<sup>52</sup>. LSAMP is a tumor suppressor gene in 332 333 osteosarcoma<sup>53</sup>, and 3q13.31 homozygous deletions have been implicated in tumorigenesis<sup>54</sup>. *TLE3* is a transcriptional corepressor involved in tumorigenesis and 334 immune function<sup>55</sup>. The transcription factor *TULP3* has been implicated in pancreatic 335 ductal adenocarcinoma and colorectal cancer<sup>56</sup>. XCL2, NMUR2, and TULP3 may also 336 337 be related to cancer progression via G-protein-coupled receptor (GPCR) signaling pathways<sup>57</sup>. JADE2 expression has been experimentally linked to NSCLC<sup>58</sup>, and has 338 been identified in GWAS of smoking behavior<sup>34</sup>. Finally, DNA damage repair 339 340 mechanisms emerge, including RPAP3, an RNA polymerase that may be involved in DNA damage repair regulation<sup>59</sup>, and *MMS22L* which repairs double strand breaks<sup>60</sup>. 341

Although smoking is the major risk factor for lung cancer, it is important to clearly disentangle the effect of smoking to fully understand the complex genetic and environmental causes of lung cancer. Our approach enables the development of new polygenic scores, which can improve precision medicine applications for lung cancer in both smokers and nonsmokers.

## 347 Author contributions statement

- 348 Drafted the manuscript: B.R.G., M.F., S.-G. J., A.K.S., E.P., A.K.D., S.P.
- 349 Acquired the data: B.R.G., S.-G. J., A.K.S., Y.S., P.D., U.S., D.D.S., W.T., J.M., S.M.,
- 350 R.R., R.J.H., J.D.M., Y.B., C.I.A., S.P.
- 351 Analyzed the data: B.R.G., S.-G. J., M.F., A.K.S., Y.S., P.D., U.S., Y.B., R.S.
- 352 Critically revised the manuscript for important intellectual content: all authors.

# 353 Acknowledgements

354 This work was supported by award #MVP000 from the United States Department 355 of Veterans Affairs (VA) Million Veteran Program. The contents of this publication are the sole responsibility of the authors and do not necessarily represent the views of VA 356 357 or the United States Government. Where authors are identified as personnel of the 358 International Agency for Research on Cancer/World Health Organization, the authors 359 alone are responsible for the views expressed in this article, and they do not necessarily 360 represent the decisions, policy, or views of the International Agency for Research on 361 Cancer/World Health Organization. Full consortium acknowledgements for MVP and the ILCCO OncoArray study<sup>7</sup> are provided in Supplementary Information. 362

363

## 364 Subject terms and techniques

365 Biological sciences > Cancer > Lung cancer

366 Biological sciences > Genetics > Genetic association study > Genome-wide association

367 studies

# 368 **Data Availability**

- 369 The full summary level association data from the individual population analyses in MVP
- 370 will be available upon publication via the dbGaP study accession number phs001672.

371

# 372 **Competing interests**

- 373 S.-G.J. is an employee and shareholder of BridgeBio Pharma. The other authors
- declare no competing interests.

### 375 Methods

### 376 Cohort definition

Patients were identified from MVP participants<sup>19</sup> utilizing clinical information 377 available through the United States Department of Veterans Affairs (VA) Corporate Data 378 379 Warehouse (CDW) with ICD codes for primary lung cancer. Occurrences of the ICD-9 380 codes 162.3, 162.4, 162.5, 162.8, and 162.9 or the ICD-10 codes C34.10, C34.11, 381 C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, and 382 C34.92 were used in case identification. Patients with secondary lung cancer were 383 excluded from the cohort using ICD-9/10 codes 197.x, C78.00, C78.01, and C78.02. 384 Additional patients were identified in the VA Cancer Registry using ICD-O site, including 385 lung/bronchus, other respiratory system or intrathoracic organs, or trachea. The Cancer 386 Registry was also used to determine the lung cancer subtypes LUAD and LUSC among 387 cases.

Preliminary totals of 18,633 and 10,845 patients with MVP participation were identified from the VA CDW and Cancer Registry, respectively. A combined cohort of 20,631 unique patients was generated for further analysis. The cohort was predominantly male (~95%) with a median age of 64–68 for sub-cohorts, depending on ancestry assignments and cancer subtypes. The cohort was curated further to remove any participant with missing data. The final cohorts are described in Supplementary Data 1.

395 Once patients were identified from VA's CDW and Cancer Registry, cases were 396 used to gather records related to age, sex, smoking status, and ancestry. Smoking 397 status included former, current, and never, based on the MVP survey at the time of

enrollment and on electronic medical records. Ancestry was defined using a machine learning algorithm that harmonizes self-reported ethnicity and genetic ancestry (HARE)<sup>61</sup>. All analyses described here were performed on patients of EA or AA ancestry in ancestry-stratified cohorts. Additionally, the cohorts were further stratified by lung cancer subtypes for analysis. Matched controls were selected based on age, gender, smoking status, and HARE assignments. Age was binned into 5-year intervals for this purpose.

405 Array genotyping, genotype quality control, and principal component analysis

Genotyping and quality control were conducted as described previously<sup>62</sup>. Briefly, we removed all samples with excess heterozygosity (F statistic<-0.1), excess relatedness (kinship coefficient $\geq$ 0.1 with 7 or more MVP samples), and samples with call rates <98.5%. Additional samples with a mismatch between self-reported sex and genetic sex were removed.

411 Principal component (PC) analysis was conducted using PLINK 2.0<sup>63</sup> 412 (v2.00a3LM), on a pruned set of SNPs (window size 1Mb, step size 80,  $r^2$ <0.1, minor 413 allele frequency (MAF)<0.01, Hardy-Weinberg equilibrium *P*<1×10<sup>-10</sup>, missingness 414 rate<10%) within European ancestry (EA) and African ancestry (AA) on unrelated 415 individuals, where unrelated individuals were defined as greater than third-degree 416 relatives as previously described<sup>62</sup>. PCs were then projected onto related individuals in 417 EA.

418 Imputation

419 Prior to imputation, a within-cohort pre-phasing procedure was applied across the 420 whole cohort by chromosome using Eagle2<sup>64</sup>. Imputation was then conducted on pre-

phased genotypes using Minimac4<sup>65</sup> and the 1000 Genomes Phase 3 (v5) reference 421 panel<sup>66</sup> in 20Mb chunks and 3Mb flanking regions. Quality of imputation (Minimac Rsq 422 or INFO) was then re-computed in EA and AA separately to be used as filters for 423 424 respective GWAS. Imputed loci reaching genome-wide significance were tested for 425 deviation from Hardy-Weinberg equilibrium (HWE) in 61,538 EA controls 426 (Supplementary Data 23). Of the 93 conditionally independent SNPs across the GWAS analyses, 6 SNPs had a significant ( $P < 1 \times 10^{-6}$ ) HWE signal; unsurprisingly, the 427 428 strongest HWE signal was from SNPs in the Major Histocompatibility Complex region. 429 However, none of the 12 novel loci reported in Table 1 significantly deviated from HWE.

### 430 Association analyses

431 For the EA lung cancer overall and subtype GWAS, we performed standard logistic regression using PLINK 2.0 (v2.00a2LM)<sup>63</sup> with a matched control design. EA 432 433 GWAS was performed in unrelated individuals, defined as greater than third-degree 434 relatives. For the AA lung cancer overall and subtype analyses, because the case 435 numbers were smaller, we performed a mixed-model logistic regression using REGENIE (v1.0.6.7)<sup>67</sup>; REGENIE applies a whole genome regression model to control 436 437 for relatedness and population structure, and includes a Firth correction to control for 438 bias in rare SNPs as well as case-control imbalance. GWAS covariates for each 439 ancestry included age, age-squared, sex, and smoking status as a categorical variable 440 (current, former, never), and the first ten principal components. Participants with missing 441 smoking status (n=786) were removed.

442 EA meta-analysis

We performed inverse-variance weighted meta-analyses of MVP-EA summary statistics and summary statistics previously reported by ILCCO<sup>7</sup> using METAL (v20100505)<sup>68</sup> with scheme STDERR. Significant inflation across GWAS and metaanalyses was not observed (all genomic control values ( $\lambda$ ) for GWAS in this study ≤1.15). Only variants present in both studies were meta-analyzed. We further performed a sensitivity analysis using the Han-Eskin random effects model (RE2) in METASOFT v2.0.1 <sup>33</sup>.

450 Lung eQTL consortium

451 The lung tissues used for eQTL analyses were from human subjects who 452 underwent lung surgery at three academic sites: Laval University, University of British 453 Columbia (UBC), and University of Groningen. Genotyping was carried out using the 454 Illumina Human1M-Duo BeadChip. Expression profiling was performed using an 455 Affymetrix custom array (see GEO platform GPL10379). Only samples that passed 456 genotyping and gene expression quality controls were considered for eQTL analysis, leaving sample sizes of 409 for Laval, 287 for UBC, and 342 for Groningen. Within each 457 set, genotypes were imputed in each cohort with the Michigan Imputation Server<sup>65</sup> using 458 the Haplotype Reference Consortium<sup>69</sup> version 1 (HRC.r1-1) data as a reference set, 459 460 and gene expression values were adjusted for age, sex, and smoking status. Normalized gene expression values from each set were then combined with ComBat<sup>70</sup>. 461 462 eQTLs were calculated using a linear regression model and additive genotype effects as implemented in the Matrix eQTL package in R<sup>71</sup>. Cis-eQTLs were defined by a 2 Mb 463 464 window, i.e., 1 Mb distance on either side of lung cancer-associated SNPs. Pre-

465 computed lung eQTLs were also obtained from the Genotype-Tissue Expression
466 (GTEx) Portal<sup>20</sup>. Lung eQTLs in GTEx (version 8) are based on 515 individuals and
467 calculated using FastQTL<sup>72</sup>.

468 Fine-mapping

469 We performed Bayesian fine-mapping the genome-wide significant loci from EA pipeline<sup>73</sup> 470 meta-analysis and AA using FinnGen fine-mapping the (https://github.com/FINNGEN/finemapping-pipeline) and SuSiE<sup>25,26</sup>. Pairwise SNP 471 472 correlations were calculated directly from imputed dosages on European-ancestry MVP samples from this analysis using LDSTORE 2.0<sup>73</sup>. The maximum number of allowed 473 474 causal SNPs at each locus was set to 10. Fine-mapping regions which overlapped the 475 major histocompatibility complex (MHC; chr6:25,000,000-34,000,000) were excluded. High quality credible sets were defined as those with minimum  $r^2 < 0.5$  between variants. 476 477 The functional consequences of the AA credible set variants were annotated using the Variant Effect Predictor (VEP)<sup>31</sup>. 478

479 Replication analysis

480 External replication was performed for all genome-wide significant associations in overall lung cancer, LUAD, and LUSC in OncoArray Consortium Lung Study 481 (OncoArray)<sup>8,74</sup>. Replication for genome-wide significant multi-ancestry associations 482 483 was performed in a fixed effects meta-analysis of OncoArray CEU Europeans for 484 significant EA meta-analysis associations, and in an YRI AA meta-analysis composed of 5 studies<sup>8</sup> for significant MVP AA associations. Meta-analysis associations from this 485 486 study were replicated against a meta-analysis of these OncoArray groups. To replicate 487 significant variants from EA analysis conditioned on smoking, pack-years was

additionally included as a covariate in replication cohorts. There was no participant overlap between the replication cohorts and the ILCCO study<sup>7</sup> used in the discovery scan. Covariates included the first five genetic principal components and participant study sites. Proxy SNPs were used to replicate known associations at rs75675343 (rs2318539/4:67831628:C:A;  $R^{2}_{EUR}=1$ ) and rs4586884 (rs4435699/4:164019500:C:G;  $R^{2}_{EUR}=0.999$ ).

494

#### 495 *Multi-ancestry meta-analysis*

A multi-ancestry meta-analysis of MVP EA and AA cohorts with summary 496 statistics previously reported by ILCCO<sup>7</sup> was conducted in METAL<sup>68</sup> using an inverse 497 498 variance-weighted fixed effects scheme. Only variants present in two or more cohorts 499 were meta-analyzed. Index variants were defined using the two-stage "clumping" procedure implemented in the Functional Mapping and Annotation (FUMA) platform<sup>75</sup>. 500 501 In this process, genome-wide significant variants are collapsed into LD blocks ( $r^2$ >0.6) 502 and subsequently re-clumped to yield approximately independent ( $r^2 < 0.1$ ) signals; 503 adjacent signals separated by <250kb are ligated to form independent loci. Novel 504 variants are defined as meta-analysis index variants located >1Mb from previously 505 reported lung cancer associations. We additionally performed a sensitivity analysis using the random effects model (RE2) in METASOFT v2.0.1<sup>33</sup>. 506

507 Polygenic risk score (PRS) calculation

508 We used PRS-CS<sup>76</sup> to generate effect size estimates under a Bayesian 509 shrinkage framework, and then used PLINK 2.0  $(v2.00a3LM)^{63}$  to linearly combine 510 weights into a risk score using a global shrinkage prior of  $1 \times 10^{-4}$ , which is

recommended for less polygenic traits. Finally, scores were normalized to a mean of 0and a standard deviation of 1.

513 Multi-trait analyses

In order to remove all residual effects of smoking on lung cancer susceptibility, we conducted a multi-trait meta-analysis<sup>35</sup> conditioned on cigarettes per day, which was shown to be most significantly correlated with all lung cancer GWAS<sup>34</sup>. The metaanalysis was performed on the EA meta-analysis summary statistics using mtCOJO, part of the GCTA software package<sup>77</sup>. An LD reference was constructed from 50,000 MVP EA samples.

Multi-trait analysis of GWAS (MTAG)<sup>45</sup> (v0.9.0) was applied using genome-wide 520 521 LUSC summary statistics after conditioning on cigarettes per day, and estrogen receptor negative (ER-) breast cancer summary statistics<sup>46</sup> which were munged using 522 LDSC (v1.01)<sup>38</sup>. Single causal variant colocalization between LUSC conditioned on 523 524 cigarettes per day and ER- breast cancer was performed using Coloc (R; version 4)<sup>78</sup> 525 for variants at ABHD8 (chr19: 17,350,000 to 17,475,000). A posterior probability > 0.9 for Hypothesis 4 (both traits are associated and share a single causal variant) was used 526 527 as the criteria for colocalization.

528 Heritability and genetic correlations

Linkage Disequilibrium score regression (LDSC) v1.0.1 was used to calculate observed-scale SNP-heritability<sup>38</sup> using lung cancer and subtypes summary statistics, before and after conditioning on cigarettes per day. Pairwise genetic correlations were estimated between lung cancer and subtypes from MVP, ILCCO<sup>7</sup>, and EA meta-

analysis, and four smoking traits (smoking initiation, cigarettes per day, smoking
 cessation, and age of initiation)<sup>34</sup>.

535 Conditional and joint SNP analysis

To find independently associated genome-wide significant SNPs at each locus in 536 537 a stepwise fashion, we used GCTA-COJO using the --cojo-slct option. An LD reference 538 was constructed from 50,000 MVP EA samples. Variants with MAF<0.01 in the COJO reference panel were not included in identification of independent signals. LDTrait<sup>79</sup> was 539 540 queried to identify previously published significant GWAS variants within 1Mb of our 541 index variants in all populations. Novel loci were defined as those at which the index 542 variant was not within ±500 kb of previously reported genome-wide significant lead 543 SNPs for lung cancer or its subtypes in any ancestry.

544 Phenome-wide association study (PheWAS)

We conducted a PheWAS of electronic health record-derived phenotypes and lab 545 546 results in EA subjects using either the normalized PRS as the predictor or 547 independently associated genome-wide significant SNPs. Comparison of unconditioned 548 PRS PheWAS and conditioned PRS PheWAS were based on ILCCO summary 549 statistics<sup>7</sup> and used MVP EA as the out-of-sample test set. Associations were tested using the R PheWAS package<sup>80</sup> version 0.1 with QC procedures described previously<sup>81</sup>. 550 551 Control sex-based exclusion applied. and criteria were

# 2 Main Tables

**Table 1**: Novel genome-wide significant loci and their respective index variants associated with lung cancer risk in European-ancestry meta-analyses from MVP and ILCCO<sup>7</sup> cohorts, MVP African ancestry, multi-ancestry meta-analyses, and in European-ancestry meta-analyses after conditioning on cigarettes per day. LUAD, adenocarcinoma; LUSC, squamous cell carcinoma; EA, effect allele; NEA, non-effect allele; EAF, effect allele frequency in the given population; OR (95% CI), odds ratio and 95% confidence interval.

Lung cancer subtype	rsID	Cytoband	Position (hg19)	Candidate gene	EA	NEA	EAF	Discovery OR (95% CI)	Discovery P	Replication OR (95% CI)	Replication <i>P</i>	Combined meta- analysis OR (95% CI)	Combined meta-analysis <i>P</i>
Novel loci f	rom the Euro	pean ances	stry GWAS m	eta-analysis	s								
Overall	rs77045810	1q24.2	168,505,017	XCL2	А	С	0.89	1.10 (1.07, 1.13)	1.43×10 <sup>-10</sup>	1.07 (1.02, 1.13)	0.0057	1.09 (1.07, 1.12)	3.94×10 <sup>-12</sup>
Overall	rs144840030	3q13.31	117,147,326	LSAMP	Т	G	0.01	1.31 (1.19, 1.44)	1.09×10 <sup>-8</sup>	1.07 (0.88, 1.30)	0.49	1.26 (1.16, 1.37)	5.01×10 <sup>-8</sup>
Overall	rs62400619	5q33.1	152,343,053	NMUR2	Т	С	0.68	1.06 (1.04, 1.08)	6.33×10 <sup>-9</sup>	1.03 (0.99, 1.06)	0.16	1.05 (1.03, 1.07)	1.10×10 <sup>-8</sup>
Overall	rs9988980	12p13.33	3,038,917	TULP3	Т	С	0.39	1.05 (1.04, 1.08)	5.34×10 <sup>-8</sup>	1.05 (1.02, 1.09)	0.0022	1.05 (1.04, 1.07)	3.72×10 <sup>-10</sup>
LUAD	rs67824503	8q24.21	129,535,264	MYC	Т	С	0.75	1.10 (1.07, 1.14)	1.81×10 <sup>-8</sup>	1.11 (1.05, 1.16)	5.05×10 <sup>-5</sup>	1.10 (1.07, 1.14)	4.09×10 <sup>-12</sup>
LUAD	rs11855650	15q23	70,431,773	TLE3	Т	G	0.38	1.09 (1.06, 1.12)	1.12×10 <sup>-8</sup>	1.12 (1.07, 1.17)	1.22×10 <sup>-7</sup>	1.10 (1.07, 1.13)	1.15×10 <sup>-14</sup>
LUSC	rs36229791	10q24.31	101,991,135	BLOC1S2	А	Т	0.04	1.27 (1.17, 1.38)	4.04×10 <sup>-8</sup>	1.25 (1.12, 1.41)	1.49×10 <sup>-4</sup>	1.26 (1.18, 1.35)	2.48×10 <sup>-11</sup>

#### Novel loci from the African ancestry GWAS

Overall	rs78994068	12q24.32 127,225,803	LINC00944 C	A 0.01	2.13 (1.66, 2.72)	1.87×10 <sup>-9</sup>	1.026 (0.681, 1.548)	0.90	1.76 (1.42, 2.17)	1.81×10 <sup>-7</sup>
---------	------------	----------------------	-------------	--------	-------------------	-----------------------	----------------------	------	-------------------	-----------------------

Novel loci from the multi-ancestry meta-analysis (not genome-wide significant in the European meta-analysis)

Overall	rs329122	5q31.1	133,864,599	JADE2	A	G	0.43	0.95 (0.93, 0.97)	1.12×10 <sup>-8</sup>	0.97 (0.94, 1.00)	0.053	0.96 (0.94, 0.97)	3.69×10 <sup>-9</sup>
Overall	rs7300571	12q13.11	47,857,826	RPAP3	т	С	0.11	1.08 (1.05, 1.12)	3.47×10 <sup>-8</sup>	1.07 (1.02, 1.13)	0.0044	1.08 (1.06, 1.11)	6.48×10 <sup>-10</sup>

### Novel loci after conditioning on cigarettes per day from the European ancestry GWAS meta-analysis

Overall	rs1124241	6q16.1	97,722,453	MMS22L	А	G	0.22 1.08 (1.05, 1.11)	1.26×10 <sup>-8</sup>	1.06 (1.02, 1.11)	0.0062	1.08 (1.05, 1.10)	3.39×10 <sup>-10</sup>
LUSC	rs61494113	19p13.11	17,401,859	ABHD8	A	G	0.29 1.12 (1.07, 1.16)	4.90×10 <sup>-8</sup>	1.10 (1.03, 1.17)	0.0031	1.11 (1.08, 1.15)	6.39×10 <sup>-10</sup>

### 560 Main Figure captions

561 Figure 1. Highlighted novel GWAS loci. a-d) The meta-analysis of squamous cell 562 lung carcinoma (LUSC) in European ancestry (EA) identifies a novel locus at 10g24.31. 563 a) Odds ratios for rs36229791 in LUSC compared to lung adenocarcinoma (LUAD) and 564 overall lung cancer. b) BLOC1S2 expression varies by genotype at rs36229791. c) 565 BLOC1S2 eQTL t statistic vs LUSC z statistic. d) Regional association plot showing 566 SNP significance and genes around lead SNP rs36229791. e) The African ancestry 567 GWAS highlights a putatively novel locus on chr12 at LINC00944. The risk allele has effectively 0% frequency in EA. 568

569

570 Figure 2. Association of lung cancer GWAS with smoking behaviors. a) Genetic 571 correlations (with 95% confidence interval) between the lung cancer GWAS and 572 smoking behaviors, including smoking initiation, cigarettes per day, smoking cessation, 573 and age of initiation. b) SNP heritability for the meta-analysis and conditional meta-574 analysis. The heritability decreases in the conditional analysis for overall lung cancer as 575 well as both subtypes, suggesting that some portion of the heritability of lung cancer is 576 due to smoking behavior. c) Polygenic risk scores (PRS) based on standard lung 577 cancer GWAS (blue) performs worse in never-smokers than former or current smokers, 578 while conditioning on smoking behavior (orange) results in similar performance.

579

580 **Figure 3. Forest plot of genome-wide significant associations.** Within each cancer 581 subtype, changes in effect size and significance are shown before and after conditioning

582 on cigarettes per day. Novel loci are indicated by an asterisk after the gene name (\*). 583 Loci that became significant after conditioning ( $P < 5 \times 10^{-8}$ ) are in red.

584

Figure 4. Significant locus after conditioning on smoking behavior, 19p13.11, has pleiotropic associations with ER-negative breast cancer. a) Regional association plot of the 19p13.11 multi-trait analysis of GWAS (MTAG) locus. b) Odds ratios for lead SNP rs61494113 in squamous cell lung carcinoma (LUSC), before and after conditioning, and MTAG analysis, compared to lung adenocarcinoma and overall lung cancer. c) *ABHD8* expression varies by genotype at rs61494113. d) *ABHD8* eQTL t statistic vs LUSC z statistic; red X's indicate the 95% credible set.

592

Figure 5. Phenome-wide association study (PheWAS) of polygenic risk scores (PRS) of lung cancer and lung cancer conditioned on cigarettes per day. a) PheWAS of PRS on lung cancer is mostly confounded with smoking associations. b) PheWAS of the conditional meta-analysis PRS shows associations with skin cancer and metabolic traits.

# 598 Supplementary Figure captions

599

600 Supplementary Fig. 1. Study overview. Genome-wide association studies were 601 performed in Million Veteran Program (MVP) European and African ancestry (AA) 602 cohorts for overall lung cancer, adenocarcinoma, and squamous cell carcinoma. MVP 603 and International Lung Cancer Consortium OncoArray (ILCCO) European cohorts were 604 meta-analyzed, and further meta-analyzed with AA for multi-ancestry meta-analysis. 605 Multi-trait conditional meta-analysis was performed on EA using average cigarettes per day from Liu et al. (2019). Replication and combined meta-analysis was performed 606 607 using external OncoArray cohorts.

608

Supplementary Fig. 2. Manhattan plots and quantile-quantile (QQ) plots for European meta-analyses. Manhattan and QQ plots are shown for a) overall lung cancer; b) lung adenocarcinoma (LUAD); and c) squamous cell lung carcinoma (LUSC). Cytoband positions for significant loci are noted in each Manhattan plot; putatively novel loci identified in this study are in red; externally replicated novel loci are indicated by a box. Genomic control ( $\lambda$ ) values, LDSC intercepts, and sample sizes are inset in QQ plots.

616

Supplementary Fig. 3. Effect allele frequency concordance between International Lung Cancer Consortium OncoArray (ILCCO) and Million Veteran Program European ancestry (EA) GWAS. (a-c) Effect allele frequency concordance for all variants tested in both studies with  $P<1\times10^{-5}$  in ILCCO for **a**) overall lung cancer, **b**)

lung adenocarcinoma, and c) squamous cell lung carcinoma. Points are styled based on significance level in MVP. (d-f) Effect size concordance for genome-wide significant variants in d) overall lung cancer, e) lung adenocarcinoma, and f) squamous cell lung carcinoma. One-to-one concordance is shown as a dashed line. Index variants from the EA meta-analysis between ILCCO and MVP are annotated by locus. Novel significant loci after meta-analysis are annotated in red.

627

Supplementary Fig. 4. Genome-wide significant novel lung cancer loci. Forest
plots (left) and regional Manhattan plots (right) for novel loci from European metaanalysis: a) XCL2, b) LSAMP, c) NMUR2, d) TUPL3, e) MYC, f) TLE3, and g)
BLOC1S2; and from multi-ancestry meta-analysis: h) JADE2; i) RPAP3.

632

Supplementary Fig. 5. Manhattan plots and quantile-quantile (QQ) plots for MVP African ancestry. Manhattan and QQ plots are shown for **a**) African ancestry overall lung cancer; **b**) lung adenocarcinoma (LUAD); and **c**) squamous cell lung carcinoma (LUSC). Cytoband positions for significant loci are noted in each Manhattan plot; putatively novel loci identified in this study are in red. Genomic control ( $\lambda$ ) values and sample sizes are inset in QQ plots.

639

Supplementary Fig. 6. Manhattan plots and quantile-quantile (QQ) plots for multiancestry meta-analyses. Manhattan and QQ plots are shown for a) the multi-ancestry
meta-analysis in overall lung cancer; b) lung adenocarcinoma (LUAD); and c)
squamous cell lung carcinoma (LUSC). Cytoband positions for significant loci are noted

in each Manhattan plot; novel loci not identified in the European meta-analysis are in red; externally replicated novel loci are indicated by a box. Genomic control ( $\lambda$ ) values and sample sizes are inset in QQ plots.

647

648 Supplementary Fig. 7. Association of the lung cancer polygenic risk score (PRS) 649 with lung cancer by smoking status. a) Association of the lung cancer PRS with 650 overall lung cancer risk. The risk of lung cancer reached an odds ratio (OR) of 2.51 651 (95% confidence interval: 1.80, 3.51) in the top decile. b) Association of the lung cancer 652 PRS with lung cancer risk in never-smokers. Among never-smokers, lung cancer risk 653 reached an OR of 2.67 (2.40, 2.98) in the top decile. c) Association of the lung cancer 654 PRS with lung cancer risk in ever-smokers with no history of lung cancer. The top PRS 655 decile was associated with an OR of 1.25 (1.18, 1.32).

656

657 Supplementary Fig. 8. Manhattan plots and quantile-quantile (QQ) plots for 658 European meta-analyses conditioned on cigarettes per day. Manhattan and QQ 659 plots for a) overall lung cancer conditioned on cigarettes per day; b) lung 660 adenocarcinoma (LUAD) conditioned on cigarettes per day; and c) squamous cell lung 661 carcinoma (LUSC) conditioned on cigarettes per day. Cytoband positions for significant 662 loci are noted in each Manhattan plot; novel loci not identified in the European meta-663 analysis are in red; externally replicated novel loci are indicated by a box. Genomic 664 control ( $\lambda$ ) values, LDSC intercepts, and sample sizes are inset in QQ plots.

665

666	Supplementary Fig. 9. Novel loci for overall lung cancer and squamous cell
667	carcinoma conditioned on smoking. Forest plots (left) and regional Manhattan plots
668	(right) for novel loci identified in the European meta-analysis conditioned on cigarettes
669	per day: a) MMS22L in overall lung cancer and b) ABHD8 in squamous cell lung cancer.
670	
671	
672	
673	
674	
675	
676	
677	
678	
679	

## 681 **References**

- Schabath, M. B. & Cote, M. L. Cancer Progress and Priorities: Lung Cancer. *Cancer Epidemiol. Biomarkers Prev.* 28, 1563–1579 (2019).
- Leiter, A., Veluswamy, R. R. & Wisnivesky, J. P. The global burden of lung cancer: current
  status and future trends. *Nat. Rev. Clin. Oncol.* 20, 624–639 (2023).
- Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and
  Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* **71**, 209–249
  (2021).
- 689 4. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. *CA Cancer J.*690 *Clin.* 72, 7–33 (2022).
- 691 5. Bossé, Y. & Amos, C. I. A Decade of GWAS Results in Lung Cancer. *Cancer Epidemiol.*692 *Biomarkers Prev.* 27, 363–379 (2018).
- 693 6. Timofeeva, M. N. *et al.* Influence of common genetic variation on lung cancer risk: meta-
- analysis of 14 900 cases and 29 485 controls. *Hum. Mol. Genet.* **21**, 4980–4995 (2012).
- 695 7. McKay, J. D. et al. Large-scale association analysis identifies new lung cancer susceptibility
- loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat. Genet.* 49,
  1126–1132 (2017).
- 8. Byun, J. et al. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237

699 controls identifies new susceptibility loci contributing to lung cancer. *Nat. Genet.* **54**, 1167–

700 1177 (2022).

9. Wang, Y. et al. SNP rs17079281 decreases lung cancer risk through creating an YY1-

- binding site to suppress DCBLD1 expression. *Oncogene* **39**, 4092–4102 (2020).
- 703 10. Zhang, T. *et al.* Genomic and evolutionary classification of lung cancer in never smokers.
  704 *Nat. Genet.* 53, 1348–1359 (2021).

11. Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-

706 smokers. *Cell* **150**, 1121–1134 (2012).

- Wang, Z. *et al.* Meta-analysis of genome-wide association studies identifies multiple lung
  cancer susceptibility loci in never-smoking Asian women. *Hum. Mol. Genet.* 25, 620–629
  (2016).
- Schabath, M. B., Cress, D. & Munoz-Antonia, T. Racial and Ethnic Differences in the
  Epidemiology and Genomics of Lung Cancer. *Cancer Control* 23, 338–346 (2016).
- 14. Long, E., Patel, H., Byun, J., Amos, C. I. & Choi, J. Functional studies of lung cancer
  GWAS beyond association. *Hum. Mol. Genet.* **31**, R22–R36 (2022).
- 5. Shi, J. *et al.* Genome-wide association study of lung adenocarcinoma in East Asia and
  comparison with a European population. *Nat. Commun.* **14**, 3043 (2023).
- 16. Dai, J. *et al.* Identification of risk loci and a polygenic risk score for lung cancer: a large-
- scale prospective cohort study in Chinese populations. *Lancet Respir Med* **7**, 881–891
- 718 (2019).
- 719 17. Nahar, R. *et al.* Elucidating the genomic architecture of Asian EGFR-mutant lung
- adenocarcinoma through multi-region exome sequencing. *Nat. Commun.* **9**, 216 (2018).
- 18. Zanetti, K. A. *et al.* Genome-wide association study confirms lung cancer susceptibility loci
- on chromosomes 5p15 and 15q25 in an African-American population. *Lung Cancer* 98, 33–
  42 (2016).
- 19. Gaziano, J. M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences
  on health and disease. *J. Clin. Epidemiol.* **70**, 214–223 (2016).
- 726 20. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human
   727 tissues. *Science* 369, 1318–1330 (2020).
- Hao, K. *et al.* Lung eQTLs to help reveal the molecular underpinnings of asthma. *PLoS Genet.* 8, e1003029 (2012).
- 730 22. Bossé, Y. et al. Transcriptome-wide association study reveals candidate causal genes for
- 731 lung cancer. *Int. J. Cancer* **146**, 1862–1878 (2020).

- 732 23. Koutsami, M. K. *et al.* Centrosome abnormalities are frequently observed in non-small-cell
  733 lung cancer and are associated with aneuploidy and cyclin E overexpression. *J. Pathol.*734 209, 512–521 (2006).
- 735 24. Chan, J. Y. A clinical overview of centrosome amplification in human cancers. *Int. J. Biol.*736 Sci. 7, 1122–1144 (2011).
- Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
  selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Series B Stat. Methodol.* 82, 1273–1300 (2020).
- Zou, Y., Carbonetto, P., Wang, G. & Stephens, M. Fine-mapping from summary data with
  the 'Sum of Single Effects' model. *PLoS Genet.* **18**, e1010299 (2022).
- 742 27. de Goede, O. M. *et al.* Population-scale tissue transcriptomics maps long non-coding RNAs
  743 to complex disease. *Cell* 184, 2633–2648.e19 (2021).
- 28. Li, Y. *et al.* Pan-cancer characterization of immune-related IncRNAs identifies potential
  oncogenic biomarkers. *Nat. Commun.* **11**, 1000 (2020).
- 29. de Santiago, P. R. et al. Immune-related IncRNA LINC00944 responds to variations in
- 747 ADAR1 levels and it is associated with breast cancer prognosis. *Life Sci.* 268, 118956
  748 (2021).
- 30. Chen, D. *et al.* Genome-wide analysis of long noncoding RNA (IncRNA) expression in
  colorectal cancer tissues from patients with liver metastasis. *Cancer Med.* 5, 1629–1639
  (2016).
- 31. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
- 32. Saunders, G. R. B. *et al.* Genetic diversity fuels gene discovery for tobacco and alcohol
  use. *Nature* 612, 720–724 (2022).
- 755 33. Han, B. & Eskin, E. Random-effects model aimed at discovering associations in meta-
- analysis of genome-wide association studies. *Am. J. Hum. Genet.* **88**, 586–598 (2011).
- 757 34. Liu, M. et al. Association studies of up to 1.2 million individuals yield new insights into the

- 758 genetic etiology of tobacco and alcohol use. *Nat. Genet.* **51**, 237–244 (2019).
- 35. Zhu, Z. *et al.* Causal associations between risk factors and common diseases inferred from
  GWAS summary data. *Nat. Commun.* 9, 1–12 (2018).
- 36. Xue, A. *et al.* Genome-wide analyses of behavioural traits are subject to bias by misreports
  and longitudinal changes. *Nat. Commun.* **12**, 20211 (2021).
- 763 37. Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope:
- when selection bias can substantially influence observed associations. *Int. J. Epidemiol.* 47,
  226–235 (2018).
- 38. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity
  in genome-wide association studies. *Nat. Genet.* 47, 291–295 (2015).
- 39. Nguyen, M.-H., Ueda, K., Nakamura, Y. & Daigo, Y. Identification of a novel oncogene,
- 769 MMS22L, involved in lung and esophageal carcinogenesis. *Int. J. Oncol.* 41, 1285–1296
  770 (2012).
- 40. Yang, W. *et al.* Deciphering associations between three RNA splicing-related genetic
  variants and lung cancer risk. *NPJ Precis Oncol* 6, 48 (2022).
- 41. Gabriel, A. A. G. *et al.* Genetic Analysis of Lung Cancer and the Germline Impact on
  Somatic Mutation Burden. *J. Natl. Cancer Inst.* **114**, 1159–1166 (2022).
- 42. Lawrenson, K. *et al.* Functional mechanisms underlying pleiotropic risk alleles at the
- 19p13.1 breast-ovarian cancer susceptibility locus. *Nat. Commun.* **7**, 12675 (2016).
- 43. Lesseur, C. *et al.* Genome-wide association meta-analysis identifies pleiotropic risk loci for
  aerodigestive squamous cell cancers. *PLoS Genet.* **17**, e1009254 (2021).
- 44. Fachal, L. *et al.* Fine-mapping of 150 breast cancer risk regions identifies 191 likely target
- 780 genes. *Nat. Genet.* **52**, 56–73 (2020).
- 45. Turley, P. *et al.* Multi-trait analysis of genome-wide association summary statistics using
  MTAG. *Nat. Genet.* **50**, 229–237 (2018).
- 46. Michailidou, K. *et al.* Association analysis identifies 65 new breast cancer risk loci. *Nature*

784 **551**, 92–94 (2017).

47. Wallace, C. A more accurate method for colocalisation analysis allowing for multiple causal
variants. *PLoS Genet.* **17**, e1009440 (2021).

48. Gusev, A. *et al.* A transcriptome-wide association study of high-grade serous epithelial

- ovarian cancer identifies new susceptibility genes and splice variants. *Nat. Genet.* 51, 815–
  823 (2019).
- 49. Brenner, D. R. *et al.* Alcohol consumption and lung cancer risk: A pooled analysis from the
  International Lung Cancer Consortium and the SYNERGY study. *Cancer Epidemiol.* 58,

792 25–32 (2019).

50. Larsson, S. C. *et al.* Smoking, alcohol consumption, and cancer: A mendelian

randomisation study in UK Biobank and international genetic consortia participants. *PLoS Med.* **17**, e1003178 (2020).

51. Petrelli, F. et al. Association of Obesity With Survival Outcomes in Patients With Cancer: A

797 Systematic Review and Meta-analysis. *JAMA Netw Open* **4**, e213520 (2021).

52. Lan, T., Chen, L. & Wei, X. Inflammatory Cytokines in Cancer: Comprehensive

Understanding and Clinical Progress in Gene Therapy. *Cells* **10**, (2021).

800 53. Kresse, S. H. *et al.* LSAMP, a novel candidate tumor suppressor gene in human

801 osteosarcomas, identified by array comparative genomic hybridization. *Genes* 

802 Chromosomes Cancer **48**, 679–693 (2009).

803 54. Xie, J. *et al.* Copy number analysis identifies tumor suppressive lncRNAs in human

- 804 osteosarcoma. Int. J. Oncol. 50, 863–872 (2017).
- 55. Yu, G. et al. Roles of transducin-like enhancer of split (TLE) family proteins in
- 806 tumorigenesis and immune regulation. *Front Cell Dev Biol* **10**, 1010639 (2022).
- 56. Sartor, I. T. S., Recamonde-Mendoza, M. & Ashton-Prolla, P. TULP3: A potential biomarker
  in colorectal cancer? *PLoS One* 14, e0210762 (2019).
- 57. Chaudhary, P. K. & Kim, S. An Insight into GPCR and G-Proteins as Cancer Drivers. Cells

- 810 **10**, (2021).
- 811 58. Murphy, C. *et al.* An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC).

812 *Biomedicines* **11**, (2023).

- 813 59. Ni, L. et al. RPAP3 interacts with Reptin to regulate UV-induced phosphorylation of H2AX
- and DNA damage. J. Cell. Biochem. **106**, 920–928 (2009).
- 815 60. Saredi, G. et al. H4K20me0 marks post-replicative chromatin and recruits the TONSL-
- 816 MMS22L DNA repair complex. *Nature* **534**, 714–718 (2016).
- 817 61. Fang, H. et al. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-
- 818 wide Association Studies. *Am. J. Hum. Genet.* **105**, 763–772 (2019).
- 819 62. Hunter-Zinck, H. et al. Genotyping Array Design and Data Quality Control in the Million
- 820 Veteran Program. *Am. J. Hum. Genet.* **106**, 535–548 (2020).
- 63. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
  datasets. *Gigascience* 4, 7 (2015).
- 823 64. Loh, P.-R. *et al.* Reference-based phasing using the Haplotype Reference Consortium
- 824 panel. *Nat. Genet.* **48**, 1443–1448 (2016).
- 825 65. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* 48,
  826 1284–1287 (2016).
- 827 66. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.
  828 *Nature* 526, 68–74 (2015).
- 67. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
  binary traits. *Nat. Genet.* 53, 1097–1103 (2021).
- 831 68. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
- genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 833 69. McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat.
- 834 *Genet.* **48**, 1279–1283 (2016).
- 835 70. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data

- using empirical Bayes methods. *Biostatistics* **8**, 118–127 (2007).
- 837 71. Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations.

838 Bioinformatics **28**, 1353–1358 (2012).

- 839 72. Ongen, H., Buil, A., Brown, A. A., Dermitzakis, E. T. & Delaneau, O. Fast and efficient QTL
- 840 mapper for thousands of molecular phenotypes. *Bioinformatics* **32**, 1479–1485 (2016).
- 841 73. Benner, C. et al. FINEMAP: efficient variable selection using summary data from genome-

842 wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).

- 843 74. Amos, C. I. *et al.* The OncoArray Consortium: A Network for Understanding the Genetic
- 844 Architecture of Common Cancers. *Cancer Epidemiol. Biomarkers Prev.* **26**, 126–135
- 845 (2017).
- 846 75. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
  847 annotation of genetic associations with FUMA. *Nat. Commun.* 8, 1826 (2017).
- 848 76. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via
- Bayesian regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).
- 850 77. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide
- 851 complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
- 852 78. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
  853 association studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
- 79. Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring population-
- 855 specific haplotype structure and linking correlated alleles of possible functional variants.
- 856 Bioinformatics **31**, 3555–3557 (2015).
- 857 80. Carroll, R. J., Bastarache, L. & Denny, J. C. R PheWAS: data analysis and plotting tools for
  858 phenome-wide association studies in the R environment. *Bioinformatics* **30**, 2375–2376
  859 (2014).
- 860 81. Klarin, D. *et al.* Genetics of blood lipids among ~300,000 multi-ethnic participants of the
  861 Million Veteran Program. *Nat. Genet.* **50**, 1514–1523 (2018).



**Figure 1. Highlighted novel GWAS loci. a-d)** The meta-analysis of squamous cell lung carcinoma (LUSC) in European ancestry (EA) identifies a novel locus at 10q24.31. **a)** Odds ratios for rs36229791 in LUSC compared to lung adenocarcinoma (LUAD) and overall lung cancer. **b)** *BLOC1S2* expression varies by genotype at rs36229791. **c)** *BLOC1S2* eQTL t statistic vs LUSC z statistic. **d)** Regional association plot showing SNP significance and genes around lead SNP rs36229791. **e)** The African ancestry GWAS highlights a putatively novel locus on chr12 at *LINC00943/LINC00944*. The risk allele has effectively 0% frequency in EA.



**Figure 2.** Association of lung cancer GWAS with smoking behaviors. a) Genetic correlations (with 95% confidence interval) between the lung cancer GWAS and smoking behaviors, including smoking initiation, cigarettes per day, smoking cessation, and age of initiation. b) SNP heritability for the meta-analysis and conditional meta-analysis. The heritability decreases in the conditional analysis for overall lung cancer as well as both subtypes, suggesting that some portion of the heritability of lung cancer is due to smoking behavior. c) Polygenic risk scores (PRS) based on standard lung cancer GWAS (blue) performs worse in never-smokers than former or current smokers, while conditioning on smoking behavior (orange) results in similar performance.



**Figure 3. Forest plot of genome-wide significant associations.** Within each cancer subtype, changes in effect size and significance are shown before and after conditioning on cigarettes per day. Novel loci are indicated by an asterisk after the gene name (\*). Loci that became significant after conditioning (P<5×10<sup>-8</sup>) are in red.



**Figure 4. Significant locus after conditioning on smoking behavior, 19p13.11, has pleiotropic associations with ER-negative breast cancer. a)** Regional association plot of the 19p13.11 multi-trait analysis of GWAS (MTAG) locus. **b)** Odds ratios for lead SNP rs61494113 in squamous cell lung carcinoma (LUSC), before and after conditioning on cigarettes per day, and MTAG analysis, compared to lung adenocarcinoma and overall lung cancer. **c)** *ABHD8* expression varies by genotype at rs61494113. **d)** *ABHD8* eQTL t statistic vs LUSC z statistic; red X's indicate the 95% credible set.



Figure 5. Phenome-wide association study (PheWAS) of polygenic risk scores (PRS) of lung cancer and lung cancer conditioned on cigarettes per day. a) PheWAS of PRS on lung cancer is mostly confounded with smoking associations. b) PheWAS of the conditional meta-analysis PRS shows associations with skin cancer and metabolic traits.